LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
Public ClinicalTrials.gov record NCT02159066. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
The LOGIC 2 Trial A Phase II, Multi-center, Open-label Study of Sequential LGX818/MEK162 Combination Followed by a Rational Combination With Targeted Agents After Progression, to Overcome Resistance in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma.
Study identification
- NCT ID
- NCT02159066
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 158 participants
Conditions and interventions
Conditions
Interventions
- BGJ398 Drug
- BKM120 Drug
- INC280 Drug
- LEE011 Drug
- LGX818 Drug
- MEK162 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 22, 2014
- Primary completion
- Jan 9, 2023
- Completion
- Jan 9, 2023
- Last update posted
- Mar 4, 2024
2014 – 2023
United States locations
- U.S. sites
- 17
- U.S. states
- 4
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Los Angeles | Los Angeles | California | 90024 | — |
| Cancer Care Center | Los Angeles | California | 90095 | — |
| Doris Stein Research Center Building | Los Angeles | California | 90095 | — |
| Ronald Reagan UCLA Medical Center Drug Information Center Department of Pharmaceutical Services | Los Angeles | California | 90095 | — |
| UCLA Dermatology Clinic | Los Angeles | California | 90095 | — |
| UCLA Oncology Center | Los Angeles | California | 90095 | — |
| UCLA Radiology | Los Angeles | California | 90095 | — |
| Memorial Sloan Kettering Cancer Center Attn: Geny O'neill | New York | New York | 10065 | — |
| Memorial Sloan Kettering Cancer Center Inpatient Hospital & Main Campus | New York | New York | 10065 | — |
| Memorial Sloan Kettering Cancer Center- Outpatient Clinic | New York | New York | 10065 | — |
| OHSU Knight Cancer Institute | Portland | Oregon | 97201 | — |
| OHSU Center for Health and Healing 2 | Portland | Oregon | 97239 | — |
| OHSU Center for Health and Healing | Portland | Oregon | 97239 | — |
| OHSU Research Pharmacy Services | Portland | Oregon | 97239 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02159066, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 4, 2024 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02159066 live on ClinicalTrials.gov.